Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.50 |
| ▸ | CA9 | Q16790 | 11/20 | 0.50 |
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451267 | 0.84 | CA2 (0.61) | CA2CA9CA1STS | |
| SCHEMBL9451395 | 0.83 | CA2 (0.45) | CA2CA9CA1LMNASMN1; SMN2 | |
| SCHEMBL11973138 | 0.80 | CA2 (0.46) | CA2CA9CA1NFE2L2STS | |
| SCHEMBL28479379 | 0.80 | ELANE (0.61) | LMNASMN1; SMN2NFE2L2ELANEPTGS2 | |
| SCHEMBL10559419 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2NFE2L2ELANEPTGS2 | |
| Hydrazine SCHEMBL8791966 | 0.79 | LMNA (0.46) | LMNASMN1; SMN2NFE2L2ELANEPTGS2 | |
| SCHEMBL30616021 | 0.78 | SLC22A6 (0.46) | LMNASMN1; SMN2NFE2L2ELANEPTGS2 | |
| SCHEMBL9846740 | 0.78 | LMNA (0.44) | LMNASMN1; SMN2NFE2L2ELANEPTGS2 | |
| SCHEMBL196248 | 0.78 | NFE2L2 (0.47) | LMNASMN1; SMN2NFE2L2ELANEPTGS2 | |
| SCHEMBL5728043 | 0.78 | SLC22A6 (0.46) | LMNASMN1; SMN2NFE2L2ELANEPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0450487-A1 | Benzoxazine derivatives, method for their preparation and their use for treating or prophylaxis of diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-09 | — | — | EP | claimed |
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| CN-101801925-A | antiviral compounds | GILEAD SCIENCES INC | 2010-08-11 | — | — | CN | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| CN-1336363-A | Synthesis of potassium acetylsulfanilate | ZHANG YUANBIN (CN) | 2002-02-20 | — | — | CN | disclosed |
| CN-1092066-A | The 6-methyl isophthalic acid, 2,3-Evil thiazine-4 (3H)-ketone-2, the synthetic method of 2-dioxide and salt thereof | SCIENCES INST MINISTRY OF COMM (CN) | 1994-09-14 | — | — | CN | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| US-5192785-A | Sulfamates as antiglaucoma agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-09 | — | — | US | disclosed |
| EP-0450487-A1 | Benzoxazine derivatives, method for their preparation and their use for treating or prophylaxis of diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-09 | — | — | EP | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0403185-A2 | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0136142-B1 | THERMALLY DEVELOPABLE, LIGHT-SENSITIVE MATERIAL | KONICA CORPORATION (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA2 4564/4885CA9 3805/4885CA1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.